Another Set Of Eyes: US FDA Authorizes AI Software To Spot Prostate Cancer

The Paige Prostate is a first-of-its-kind digital prostate imaging analysis software that can act as an extra pair of eyes to help pathologists spot cancer cells.

The Paige Prostrate software can be used by pathologists to find cancerous cells that otherwise would go undetected
The Paige Prostrate software can be used by pathologists to find cancerous cells that otherwise would go undetected • Source: Paige.AI.

The US Food and Drug Administration has granted de novo authorization to Paige.AI.’s Paige Prostate medical software to aid pathologists in finding prostate cancer. According to the agency, clinical data shows it significantly improved the detection of cancerous cells that otherwise would have gone unnoticed.

Paige, spun off from New York’s Memorial Sloan Kettering Cancer Center, develops artificial intelligence medical software to analyze diagnostic imaging...

More from Business

More from Medtech Insight

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Execs On The Move: June 23–27, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.